Antares Pharma Inc

Type: Company
Name: Antares Pharma Inc
Nationality: United States
Web Address: http://www.antarespharma.com/
First reported 23 hours ago - Updated 22 hours ago - 5 reports

Antares Pharma Announces Additional Patent Coverage for OTREXUP

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. Tracing back to inventions made in the late 1990's, the patents capture ... [Published Benzinga.com - 22 hours ago]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Stocks Hitting 52-Week Lows

Antares Pharma (NASDAQ: ATRS) shares tumbled 3.09% to touch a new 52-week low of $3.14. Antares Pharma's PEG ratio is -0.29.eGain (NASDAQ: EGAN) shares fell 3.76% to reach a new 52-week low of $6.40. eGain's trailing-twelve-month ROE is -8.92%Aeropostale ... [Published Benzinga.com - Apr 11 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Antares Pharma Reaches New 12-Month Low at $3.25 (ATRS)

Shares of Antares Pharma (NASDAQ:ATRS) hit a new 52-week low during mid-day trading on Thursday , AnalystRatingsNetwork reports. The company traded as low as $3.25 and last traded at $3.25, with a volume of 2,013,850 shares changing hands. The stock had ... [Published American Banking News - Apr 11 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Antares Pharma Downgraded to Sell at TheStreet (ATRS)

Antares Pharma (NASDAQ:ATRS)The analysts wrote, "Antares Pharma (ATRS) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing ... [Published American Banking News - Apr 07 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 4 reports

Technical Roundup on Health Care Sector Stocks -- Research on Becton Dickinson and Co., Antares Pharma, Hooper Holmes, and Catamaran

-- /PRNewswire/ --On Wednesday, April 02, 2014, the NASDAQ Composite finished at 4,276.46, up 0.20%. The Dow Jones Industrial Average closed the session at 16,573.00, up 0.24% and the S&P 500 ended the day at 1,890.90, higher by 0.29%. The gains were ... [Published Sacramento Bee - Apr 03 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Antares Pharma: Recent Sell-Off Provides Great Entry Point

By Mark Chapman :Antares Pharma ( ATRS ) announced 4Q2013 and FY2013 results before the market open on March 13, and investors weren't impressed. The company reported 4Q2013 loss of $0.04 per share on revenue of $4.7m, which was pretty much in-line with ... [Published BioPortfolio - Mar 26 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

Antares Pharma Reports Fourth Quarter and Full Year 2013 Operating and Financial Results

By a News Reporter-Staff News Editor at Pharma Business Week Antares Pharma, Inc. (NASDAQ: ATRS) reported operating and financial results for the fourth quarter and full year ended December 31, 2013. Recent Highlights Received approval of OTREXUP (methotrexate) ... [Published Pharmacy Choice - Mar 24 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

ANTARES PHARMA : Announces LEO Pharma's Launch of OTREXUP Methotrexate Injection to Dermatologists for Adults with Psoriasis

By a News Reporter-Staff News Editor at Health & Medicine Week -- Antares Pharma, Inc. (NASDAQ: ATRS) announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate ... [Published 4 Traders - Mar 19 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Court Report

About :  Each week we will report briefly on recently filed biotech and pharma cases .Eli Lilly and Company et al. v. Accord Healthcare Inc., USA et al.1:14-cv-00389; filed March 12, 2014 in the Southern District of Indiana• Plaintiffs:  Eli Lilly and ... [Published JD Supra - Mar 18 2014]
First reported Mar 13 2014 - Updated Mar 14 2014 - 4 reports

Antares Pharma : Reports Fourth Quarter and Full Year 2013 Operating and Financial Results

Recent HighlightsReceived approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration (FDA). OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable ... [Published 4 Traders - Mar 14 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 4 reports

Antares Earns Second OTREXUP Milestone

Antares Pharma, Inc. has received a second $5 million milestone payment from LEO Pharma in connection with the launch of OTREXUP. In November 2013, the companies entered an exclusive license and promotion agreement for OTREXUP (methotrexate) for symptomatic ... [Published Contract Pharma - Mar 12 2014]
First reported Mar 10 2014 - Updated Mar 10 2014 - 4 reports

10 March 2014 Antares Pharma Announces LEO Pharmas Launch of OTREXUP Methotrexate Injection to Dermatologists for Adults with Psoriasis

Antares Pharma Announces LEO Pharmas Launch of OTREXUP Methotrexate Injection to Dermatologists for Adults with Psoriasis ... [Published Noodls - Mar 10 2014]

Quotes

The analysts wrote, "Antares Pharma (ATRS) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and deteriorating net income."
On Wednesday, Catamaran Corp. "s stock finished the session 0.29% lower at $45.23. The stock recorded a trading volume of 2.16 million shares as compared to a three months average volume of 2.13 million shares. The stock fluctuated between $45.04 and $45.91 during the session. Shares of the company traded at a PE ratio of 35.61. Catamaran Corp." s stock has advanced 1.71% in the previous three trading sessions and 0.33% in the last one month, whereas the same has fallen by 4.70% on YTD basis...

More Content

All (72) | News (51) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (0) | Press Releases (7)
sort by: Date | Relevance
Antares Pharma Announces Additional Patent Cove... [Published Benzinga.com - 22 hours ago]
Antares Pharma : Announces Additional Patent Co... [Published 4 Traders - 23 hours ago]
Antares Pharma Announces Additional Patent Cove... [Published EON Business - 23 hours ago]
Antares Pharma Announces Additional Patent Cove... [Published Business Wire Professional Services News - 23 hours ago]
Antares Pharma Announces Additional Patent Cove... [Published Business Wire Health News - 23 hours ago]
Global Epinephrine Auto-Injector Market Report [Published Channel 8 Eyewitness News - Apr 11 2014]
Global Epinephrine Auto-Injector Market Report [Published KPLC TV - Apr 11 2014]
Global Epinephrine Auto-Injector Market Report [Published Rock Hill Herald - Apr 11 2014]
Global Epinephrine Auto-Injector Market Report [Published Yahoo! Finance - Apr 11 2014]
Global Epinephrine Auto-Injector Market Report [Published OSIX News - Apr 11 2014]
Global Epinephrine Auto-Injector Market Report [Published TickerTech.com - Apr 11 2014]
Stocks Hitting 52-Week Lows [Published Benzinga.com - Apr 11 2014]
Antares Pharma Reaches New 12-Month Low at $3.2... [Published American Banking News - Apr 11 2014]
Global Insulin Delivery Devices Market to 2019 [Published Individual.com - Apr 09 2014]
Antares Pharma Downgraded to Sell at TheStreet ... [Published American Banking News - Apr 07 2014]
Technical Roundup on Health Care Sector Stocks ... [Published Sacramento Bee - Apr 03 2014]
Technical Roundup on Health Care Sector Stocks ... [Published ADVFN India - Apr 03 2014]
Technical Roundup on Health Care Sector Stocks ... [Published TickerTech.com - Apr 03 2014]
Technical Roundup on Health Care Sector Stocks ... [Published FinanzNachrichten.de - Apr 03 2014]
Technical Roundup on Health Care Sector Stocks ... [Published Reuters - Apr 03 2014]
Technical Roundup on Health Care Sector Stocks ... [Published Financial Services - Apr 03 2014]
Financial Results, Launches, Adjusted Conversio... [Published ADVFN India - Apr 03 2014]
Financial Results, Launches, Adjusted Conversio... [Published Financial Services - Apr 03 2014]
INSMED : Announces Leadership Team Transitions ... [Published 4 Traders - Apr 02 2014]
Antares Pharma: Recent Sell-Off Provides Great ... [Published BioPortfolio - Mar 26 2014]
Antares Pharma Reports Fourth Quarter and Full ... [Published Pharmacy Choice - Mar 24 2014]
ANTARES PHARMA : Announces LEO Pharma's Launch ... [Published 4 Traders - Mar 19 2014]
Medac Pharma receives patent from USPTO for tre... [Published Individual.com - Mar 19 2014]
Court Report [Published JD Supra - Mar 18 2014]
Antares Pharma's CEO Discusses Q4 2013 Results ... [Published Seeking Alpha - Mar 17 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Antares Pharma Announces Additional Patent Cove... [Published EON Business - 23 hours ago]
EWING, N.J.--(EON: Enhanced Online News)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. Tracing back to inventions made ...
Antares Pharma Announces Additional Patent Cove... [Published Business Wire Professional Services News - 23 hours ago]
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. Tracing back to inventions made in the late ...
Antares Pharma Announces Additional Patent Cove... [Published Business Wire Health News - 23 hours ago]
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. Tracing back to inventions made in the late ...
Antares Pharma Reports Fourth Quarter and Full ... [Published Business Wire Health News - Mar 13 2014]
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2013. Recent Highlights Received approval of OTREXUP (methotrexate) injection by the ...
Antares Pharma Receives Second Milestone Paymen... [Published EON Science - Mar 12 2014]
EWING, N.J.--(EON: Enhanced Online News)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma. The milestone payment was received in connection with the launch of OTREXUP and the ...
1 2 3

Press Releases

sort by: Date | Relevance
Technical Roundup on Health Care Sector Stocks ... [Published Financial Services - Apr 03 2014]
Financial Results, Launches, Adjusted Conversio... [Published Financial Services - Apr 03 2014]
Antares Pharma, Inc. [ATRS] to Ring The NASDAQ ... [Published GlobeNewswire: Acquisitions News - Feb 19 2014]
Health Care Sector Insights: ZIOPHARM Oncology,... [Published Financial Services - Dec 19 2013]
Today's Research: ZIOPHARM Oncology Inc., Antar... [Published Financial Services - Nov 22 2013]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.